An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study
As for a neoadjuvant therapy regimen with Py, an anthracycline-free regimen is feasible. Besides, platinum-containing, long-cycle taxane regimens appear to achieve superior efficacy under anthracycline-removed conditions.
Authors
- Zining Jin (ORCID: https://orcid.org/0000-0002-3806-4718)
- Shuhong Tang
- Yao Fan
- Zhaohui Li (ORCID: https://orcid.org/0000-0003-3946-0656)
- Shan Wang (ORCID: https://orcid.org/0000-0002-4562-2247)
- Bin Liu (ORCID: https://orcid.org/0000-0003-3586-8398)
- Jianguo Wen (ORCID: https://orcid.org/0000-0003-0952-118X)
- Feng Jin (ORCID: https://orcid.org/0000-0002-0325-5362)
- Xiaolan Wang (ORCID: https://orcid.org/0000-0002-5589-7244)
- Yi Zhao (ORCID: https://orcid.org/0000-0002-0742-6595)
- Dianlong Zhang (ORCID: https://orcid.org/0000-0003-2131-9814)
- Guolian Zhu
- Jia Wang (ORCID: https://orcid.org/0000-0002-2330-8505)
Institutions
- Dalian Medical University (CN)
- Fourth Affiliated Hospital of China Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- The Third People's Hospital of Dalian City (CN)
- Shenyang Fifth People Hospital (CN)
- First Hospital of China Medical University (CN)
- Affiliated Zhongshan Hospital of Dalian University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Anshan Hospital (CN)
- Seventh People's Hospital of Dalian (CN)
- China Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1016/j.tranon.2024.102173
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28